Plasma pro-opiomelanocortin, pro-adrenocorticotropin hormone, and pituitary adenoma size in dogs with Cushing's disease

Journal of Veterinary Internal Medicine

Volumn 19, Issue 1, 2005, Pages 23-28

  Granger, Nicolas ^a   De Fornel, Pauline ^a   Devauchelle, Patrick ^b   Segond, Sophie ^b   Delisle, Françoise ^b   Rosenberg, Dan ^a  

^a ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^b Veterinary Anticancer Center   (France)

Author keywords

Canine; Corticotroph tumors; Diagnosis; Enzyme immunoassay; Hyperadrenocorticism

Indexed keywords

CORTICOTROPIN; HYPOPHYSIS HORMONE; PROOPIOMELANOCORTIN;

ARTICLE; BRAIN SIZE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CUSHING DISEASE; DIAGNOSTIC IMAGING; DOG; DOG DISEASE; FEMALE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HYPERPITUITARISM; HYPOPHYSIS ADENOMA; MALE; NONHUMAN; PREDICTION; SENSITIVITY AND SPECIFICITY; TUMOR DIAGNOSIS; TUMOR VOLUME;

ADENOMA; ADRENOCORTICOTROPIC HORMONE; ANIMALS; CORTISONE; DOG DISEASES; DOGS; IMMUNOENZYME TECHNIQUES; PITUITARY ACTH HYPERSECRETION; PITUITARY NEOPLASMS; PRO-OPIOMELANOCORTIN; REAGENT KITS, DIAGNOSTIC;

CANIS FAMILIARIS;

EID: 13544259818     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2005)19<23:PPPHAP>2.0.CO;2     Document Type: Article

References (35)

1. Feldman EC. Distinguishing dogs with functioning adrenocortical tumors from dogs with pituitary-dependent hyperadrenocorticism. J Am Vet Med Assoc 1983;183:195-200.
2. Feldman EC, Nelson RW. Hyperadrenocorticism (Cushing's syndrome). In: Feldman EC, ed. Canine and Feline Endocrinology and Reproduction. Philadelphia, PA: WB Saunders; 2004:252-357.
3. Capen C, Krieger DT, Koestner A. Neoplasms in the adenohypophysis of dogs. A clinical and pathologic study. Vet Pathol 1967;4:301-325.
4. Peterson ME, Krieger DT, Drucker WD, Halmi NS. Immunocytochemical study of the hypophysis in 25 dogs with pituitary-dependent hyperadrenocorticism. Acta Endocrinol (Copenh) 1982;101:15-24.
5. Sarfaty D, Carrillo JM, Peterson ME. Neurologic, endocrinologic, and pathologic findings associated with large pituitary tumors in dogs: Eight cases (1976-1984). J Am Vet Med Assoc 1988;193:854-856.
6. Nelson RW, Ihle SL, Feldman EC. Pituitary macroadenomas and macroadenocarcinomas in dogs treated with mitotane for pituitary-dependent hyperadrenocorticism: 13 cases (1981-1986). J Am Vet Med Assoc 1989;194:1612-1617.
7. Kipperman BS, Feldman EC, Dybdal NO, Nelson RW. Pituitary tumor size, neurologic signs, and relation to endocrine test results in dogs with pituitary-dependent hyperadrenocorticism: 43 cases (1980-1990). J Am Vet Med Assoc 1992;201:762-767.
8. White A, Gibson S. ACTH precursors: Biological significance and clinical relevance. Clin Endocrinol (Oxf) 1998;48:251-255.
9. Benjannet S, Rondeau N, Day R, et al. PC1 and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues. Proc Natl Acad Sci U S A 1991;88:3564-3568.
10. Zhou A, Bloomquist BT, Mains RE. The prohormone convertases PC1 and PC2 mediate distinct endoproteolytic cleavages in a strict temporal order during proopiomelanocortin biosynthetic processing. J Biol Chem 1993;268:1763-1769.
11. Raffin-Sanson ML, de Keyzer Y, Bertagna X. Proopiomelanocortin, a polypeptide precursor with multiple functions: From physiology to pathological conditions. Eur J Endocrinol 2003;149:79-90.
12. Fuller PJ, Lim AT, Barlow JW, et al. A pituitary tumor producing high molecular weight adrenocorticotropin-related peptides: Clinical and cell culture studies. J Clin Endocrinol Metab 1984;58:134-142.
13. Hale AC, Millar JB, Ratter SJ, et al. A case of pituitary dependent Cushing's disease with clinical and biochemical features of the ectopic ACTH syndrome. Clin Endocrinol (Oxf) 1985;22:479-488.
14. Raffin-Sanson ML, Massias JF, Dumont C, et al. High plasma proopiomelanocortin in aggressive adrenocorticotropin-secreting tumors. J Clin Endocrinol Metab 1996;81:4272-4277.
15. Gibson S, Ray DW, Crosby SR, et al. Impaired processing of proopiomelanocortin in corticotroph macroadenomas. J Clin Endocrinol Metab 1996;81:497-502.
16. Kooistra HS, Voorhout G, Mol JA, Rijnberk A. Correlation between impairment of glucocorticoid feedback and the size of the pituitary gland in dogs with pituitary-dependent hyperadrenocorticism. J Endocrinol 1997;152:387-394.
17. Bosje JT, Rijnberk A, Mol JA, et al. Plasma concentrations of ACTH precursors correlate with pituitary size and resistance to dexamethasone in dogs with pituitary-dependent hyperadrenocorticism. Domest Anim Endocrinol 2002;22:201-210.
18. Mol JA, van Mansfeld AD, Kwant MM, et al. The gene encoding proopiomelanocortin in the dog. Acta Endocrinol (Copenh) 1991;125(Suppl 1):77-83.
19. Ginel PJ, Perez-Rico A, Moreno P, Lucena R. Validation of a commercially available enzyme-linked immunosorbent assay (ELISA) for the determination of cortisol in canine plasma samples. Vet Res Commun 1998;22:179-185.
20. Hansen BL, Kemppainen RJ, MacDonald JM. Synthetic ACTH (cosyntropin) stimulation tests in normal dogs: Comparison of intravenous and intramuscular administration. J Am Anim Hosp Assoc 1994;30:38-41.
21. Héripret D. Comparison of ACTH response test, low dose dexamethasone suppression test and urine cortisol: Creatinine ratio as screening tests in canine hyperarenocorticism. Prat Méd Chir Anim Comp 1995;30:309-317.
22. Feldman EC. Comparison of ACTH response and dexamethasone suppression as screening tests in canine hyperadrenocorticism. J Am Vet Med Assoc 1983;182:506-510.
23. Feldman EC, Stabenfeldt GH, Farver TB, Addiego LA. Comparison of aqueous porcine ACTH with synthetic ACTH in adrenal stimulation tests of the female dog. Am J Vet Res 1982;43:522-524.
24. Feldman EC, Bohannon NV, Tyrrell JB. Plasma adrenocorticotropin levels in normal dogs. Am J Vet Res 1977;38:1643-1645.
25. Scott-Moncrieff JC, Koshko MA, Brown JA, et al. Validation of a chemiluminescent enzyme immunometric assay for plasma adrenocorticotropic hormone in the dog. Vet Clin Pathol 2003;32:180-187.
26. Stewart PM, Gibson S, Crosby SR, et al. ACTH precursors characterize the ectopic ACTH syndrome. Clin Endocrinol (Oxf) 1994;40:199-204.
27. OCTEIA POMC technical notice AC-71F1, Issue 1, Boldon, Tyne and Wear, UK: Immunodiagnostic Systems Limited; November 2002:1-12.
28. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation - A revisit with a decade of progress. Pharm Res 2000;17:1551-1557.
29. Kojima Y, Suzuki S, Yamamura K, et al. Comparison of ACTH secretion in Cushing's adenoma and clinically silent corticotroph adenoma by cell immunoblot assay. Endocr J 2002;49:285-292.
30. Ohta S, Nishizawa S, Oki Y, et al. Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotroph pituitary adenoma of subtype I - Immunohistochemical study. Pituitary 2002;5:221-223.
31. Thorner MO, Vance ML, Laws ER, et al. The anterior pituitary. In: Wilson JD, Foster DW, Kronenberg HMLPR, ed. Williams Textbook of Endocrinology. Philadelphia, PA: WB Saunders; 1998:249-340.
32. Theon AP, Feldman EC. Megavoltage irradiation of pituitary macrotumors in dogs with neurologic signs. J Am Vet Med Assoc 1998;213:225-231.
33. Bertoy EH, Feldman EC, Nelson RW, et al. Magnetic resonance imaging of the brain in dogs with recently diagnosed but untreated pituitary-dependent hyperadrenocorticism. J Am Vet Med Assoc 1995;206:651-656.
34. Duesberg CA, Feldman EC, Nelson RW, et al. Magnetic resonance imaging for diagnosis of pituitary macrotumors in dogs. J Am Vet Med Assoc 1995;206:657-662.
35. Bertoy EH, Feldman EC, Nelson RW, et al. One-year follow-up evaluation of magnetic resonance imaging of the brain in dogs with pituitary-dependent hyperadrenocorticism. J Am Vet Med Assoc 1996;208:1268-1273.